Analysis of 2'5' oligo (A) synthetase in patients with advanced thyroid carcinoma.
Vainas
I
I
Dimitriadis
K
K
Stergiou
I
I
Tsirintanis
I
I
Galaktidou
G
G
Kortsaris
A H
AH
D015088:2',5'-Oligoadenylate Synthetase / Q000097:blood*; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016190:Carboplatin / Q000008:administration & dosage; D002277:Carcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000628:therapy; D003131:Combined Modality Therapy; D004790:Enzyme Induction / Q000187:drug effects; D015251:Epirubicin / Q000627:therapeutic use; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007155:Immunologic Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016898:Interferon-alpha / Q000494:pharmacology* / Q000627:therapeutic use; D011446:Prospective Studies; D013964:Thyroid Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000628:therapy
D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D007155:Immunologic Factors; D016898:Interferon-alpha; D015251:Epirubicin; D005047:Etoposide; D016190:Carboplatin; D015088:2',5'-Oligoadenylate Synthetase; D007069:Ifosfamide